Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
ViiV applies for FDA approval of HIV drug fostemsavir
The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.
Given to treatment-experienced people with HIV, the attachment inhibitor BMS-663068 (fostemsavir) demonstrated potentcy in the range of...
Futuristic highlights from the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
Bristol-Myers Squibb reported encouraging preliminary results from a short study evaluating its oral version of a new class of...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.